

CEPI



COVAX & the COVAX Facility

Brief update to WHO Member States

23 December 2020

COVAX 2020 high-level achievements

*per 18 Dec 2020
announcements*

COVAX now has **agreements for 2B doses** of promising vaccine candidates, and **has laid the groundwork for further doses** to be secured through donor contributions


All 190 participating & eligible COVAX economies will be able to **access doses to protect high-risk groups in the first half of 2021**

At least 1.3 B doses will be available for 92 COVAX AMC-eligible economies, targeting **up to 20% coverage by end 2021**

These agreements, with funds raised in 2020 & early pledges for 2021, offer clearest path to end the pandemic's acute phase globally

COVAX has negotiated to contract ~3 Bn doses

COVAX secured volume, in M doses (2021 and 2022)



1. The COVAX Facility has secured right of first refusal on some candidates that received investments from the COVAX R&D portfolio (led by CEPI)

2. Single dose regimen; no adjustment to 2 dose regimen

Principles for dose-sharing with COVAX



COVAX is accelerating its work to complement the Facility's procured doses with donations. **The Principles for Dose-Sharing** provide a way for high-income economies to make additional volumes from bilateral deals available primarily to AMC participants, **on an equitable basis.**



The following Principles for Shared Doses aim to maximize their impact:

- Safe and effective
- Early availability
- Rapidly deployable
- Unearmarked
- Substantive quantity



Shared doses are ideally paid for by the dose-sharing country, including ancillary costs. The Facility ensures these doses are distributed equitably, effectively & transparently while supporting readiness in AMC economies.

COVAX welcomes commitments by potential dose-sharing countries and manufacturers to adopt these principles and to partner with COVAX to provide additional doses for equitable distribution.